All News

Found 96 articles

• MindMed To Evaluate Ayahuasca's Active Ingredient DMT In Phase 1 Clinical Trial Collaboration

  6/18/2020

  Phase 1 Trial to experiment with dosing methods to better understand how humans react to DMT, setting stage for future potential Phase 2a proof of concept trials

• Phase 2 Clinical Trial of LSD for "Suicide Headaches" Begins Treating Patients

  6/8/2020

  MindMed Is Collaborating on a Phase 2 Clinical Trial of LSD For Cluster Headaches with University Hospital Basel's Liechti Lab

• MindMed Launches Project Lucy Focused on LSD Experiential Therapy For Anxiety Disorders

  6/4/2020

  Targeting a Phase 2b psychedelic assisted therapy trial for the treatment of anxiety disorders

• MindMed's Microdosing Division Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD

  6/2/2020

  Adds Clinical Trial Site at University Hospital Basel and Appoints World Leading Psychedelics Researcher Dr. Matthias Liechti as Principal Investigator

• MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies

  5/27/2020

  MindMed Further Expands R&D Collaboration with University Hospital Basel's Liechti Lab with Plans To Develop Next-Gen Psychedelic Therapies Combining LSD and MDMA

• Psychedelic Pharmaceutical Company MindMed Develops LSD Neutralizer Technology To Shorten and Stop LSD Trips

  4/21/2020

  Advances Discovered in Collaboration with University Hospital Basel's Liechti Laboratory and Aims To Enhance Therapeutic Potential of Psychedelics

• MindMed Promotes Jeanne Bonelle to Executive Vice President, Technical Operations

  4/20/2020

  Company is actively developing and scaling manufacturing processes for 18-MC and LSD APIs to be used in the company's future drug trials

• MindMed Announces U.S. Trading on the OTCQB Venture Market Under Symbol MMEDF

  4/17/2020

  Mind Medicine Inc., the leading psychedelic pharmaceutical company, is pleased to announce that the Company has graduated from the OTC Pink Open Market to the OTCQB Venture Market.

• REPEAT: MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC

  4/17/2020

  Mind Medicine Inc., the leading psychedelic pharmaceutical company, has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC.

• MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC

  4/16/2020

  Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading psychedelic pharmaceutical company, has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC.

• 

  BioSpace Global Roundup, April 2

  4/2/2020

  Biopharma companies from across the globe provide updates on their pipelines and business practices.

• MindMed Acquires Exclusive License to Eight Clinical Trials of LSD, Partners with World-Leading Psychedelic Research Laboratory at University Hospital Basel

  4/1/2020

  Multi-year deal gives MindMed access to largest collection of clinical trials & knowhow for LSD psychedelic research including a Phase 2 clinical trial of LSD for the treatment of anxiety

• MindMed Reports 2019 Year-end Results and Corporate Update

  3/30/2020

  Mind Medicine Inc. announced the release of its audited consolidated financial statements and accompanying management's discussion and analysis for the period from May 30, 2019, date of incorporation, to December 31, 2019.

• Leading Psychedelic Pharmaceutical Company MindMed Forms New Board Committee To Evaluate Acquisitions And Scientific Collaborations

  3/12/2020

  John Hopkins professor and psychedelics expert Matthew Johnson to act as senior advisor to committee

• MindMed Lists on NEO to Become World’s First Psychedelic Pharmaceutical Company to Go Public

  3/3/2020

  NEO is pleased to announce it has granted final approval to Mind Medicine Inc., the leading neuro-pharmaceutical company for psychedelic-inspired medicines, to make its global public markets debut.

• Mindmed Acquires Opioid Addiction Drug Candidate Based on the Natural Psychedelic Ibogaine

  9/16/2019

  Mind Medicine, Inc. ("Mindmed"), the leading neuro-pharmaceutical company focused on discovering and developing medicines based on psychedelics, has finalized the acquisition of the 18-MC drug development program, an anti-addictive molecule that was previously funded by the National Institute on Drug Abuse ("NIDA")